Regulatory challenges with biosimilars: an update from 20 countries
Authors:
Open Access
- 21 November 2020
- journal article
- research article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1491 (1) , 42-59
Abstract
The World Health Organization (WHO) issued guidelines for the regulatory evaluation of biosimilars in 2009 and has provided considerable effort toward helping member states implement the evaluation principles in the guidelines into their regulatory practices. Despite this effort, a recent WHO survey (conducted in 2019–2020) has revealed four main remaining challenges: unavailable/insufficient reference products in the country; lack of resources; problems with the quality of some biosimilars (and even more with noninnovator products); and difficulties with the practice of interchangeability and naming of biosimilars. The following have been identified as opportunities/solutions for regulatory authorities to deal with the existing challenges: (1) exchange of information on products with other regulatory authorities and accepting foreign licensed and sourced reference products, hence avoiding conducting unnecessary (duplicate) bridging studies; (2) use of a “reliance” concept and/or joint review for the assessment and approval of biosimilars; (3) review and reassessment of the products already approved before the establishment of a regulatory framework for biosimilar approval; and (4) setting appropriate regulatory oversight for good pharmacovigilance, which is essential for the identification of problems with products and establishing the safety and efficacy of interchangeability of biosimilars.Keywords
This publication has 9 references indexed in Scilit:
- WHO implementation workshop on guidelines on procedures and data requirements for changes to approved biotherapeutic products, Seoul, Republic of Korea, 25–26 June 2019Biologicals, 2020
- The regulatory landscape of biosimilars: WHO efforts and progress made from 2009 to 2019Biologicals, 2020
- Quality assessment and its impact on clinical performance of a biosimilar erythropoietin: A simulated case studyBiologicals, 2019
- Regulatory evaluation of biosimilars throughout their product life-cycleBulletin of the World Health Organization, 2018
- WHO/KFDA joint workshop on implementing WHO guidelines on evaluating similar biotherapeutic products, Seoul, Republic of Korea 24–26 August, 2010Biologicals, 2011
- Summary of the diverse situation of similar biotherapeutic products in the selected countries (August 2010)Biologicals, 2011
- Biosimilars—why terminology mattersNature Biotechnology, 2011
- Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodiesKidney International, 2011
- Pure Red-Cell Aplasia and Epoetin TherapyNew England Journal of Medicine, 2004